Expedia Group (EXPE)
(Delayed Data from NSDQ)
$128.49 USD
-4.18 (-3.15%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $128.45 -0.04 (-0.03%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EXPE 128.49 -4.18(-3.15%)
Will EXPE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EXPE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXPE
EXPE vs. CHWY: Which Stock Is the Better Value Option?
Are Investors Undervaluing Expedia Group (EXPE) Right Now?
EXPE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Expedia (EXPE) is a Top Value Stock for the Long-Term
Why Expedia (EXPE) is a Top Value Stock for the Long-Term
Booking Holdings (BKNG) Aids Travelers With Cover Genius Deal
Other News for EXPE
Expedia Group Breaks Below 200-Day Moving Average - Notable for EXPE
Morgan Stanley Sticks to Their Hold Rating for Expedia (EXPE)
Bernstein Sticks to Their Hold Rating for Expedia (EXPE)
Patient Capital Management Q2 2024 Investment Review
Patient Capital Management Q2 2024 Commentary